Status:
UNKNOWN
Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial
Lead Sponsor:
Shaheed Zulfiqar Ali Bhutto Medical University
Conditions:
Hyperbilirubinemia, Neonatal
Eligibility:
All Genders
2-7 years
Phase:
NA
Brief Summary
Fenofibrate accelerates bilirubin conjugation and excretion, decreasing the side effects of prolonged unconjugated hyperbilirubinemia in neonates. It also reduces the duration of phototherapy and thus...
Detailed Description
Complete history and examination will be carried out while patients will be screened for enrollment. After taking informed consent, eligible patients will be selected and divided into two groups A and...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Gestational age ≥ 35 weeks
- Birth weight ≥ 2 kg
- Age: 2-7 days of life
- Total serum bilirubin level ≥15mg/dl and ≤20 mg/dl
- EXCLUSION CRITERIA:
- Neonates with total bilirubin \>20mg/dl
- Conjugated bilirubin level greater than 15% of total serum bilirubin
- Maternal hyperbilirubinemia (on medical record)
- Babies with congenital anomalies (on clinical examination)
- Those not consenting to participate in the study
Exclusion
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04868019
Start Date
September 1 2021
End Date
February 1 2022
Last Update
August 24 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.